TY - JOUR
T1 - Current Considerations for Clinical Management and Care of People with HIV
T2 - Findings from the 11th Annual International HIV and Aging Workshop
AU - Kamkwalala, Asante R.
AU - Garg, Ankita
AU - Roy, Upal
AU - Matthews, Avery
AU - Castillo-Mancilla, Jose
AU - Lake, Jordan E.
AU - Sebastiani, Giada
AU - Yin, Michael
AU - Brown, Todd T.
AU - Kamer, Angela R.
AU - Jabs, Douglas A.
AU - Ellis, Ronald J.
AU - Boffito, Marta
AU - Greene, Meredith
AU - Schmalzle, Sarah
AU - Siegler, Eugenia
AU - Erlandson, Kristine M.
AU - Moore, David J.
N1 - Funding Information:
It is expected that the project will improve the general awareness of geriatric principles, assessments, and resources among clinic staff and providers, and will lead to several quality improvement projects to address identified needs. An increase in visit volume and subspecialty referral is also expected; in our clinic this was seen in appointments for HIV providers, pharmacists, nutritionists, social workers, employment counselors, housing coordinators, substance abuse counselors, and partners at the school of law for advanced directives. The key challenge to a project of this magnitude includes sustainability after grant funding no longer covers the cost of research assistants and patient incentives. Additional hurdles include duration of time to conduct assessments and to review results with patients, patient referral fatigue, lack of local resources to adequately and quickly address all identified deficiencies, and competing priorities in a population with significant socioeconomic struggles.
Funding Information:
J.E.L. has served as a consultant to Merck, ViiV, and Theratechnologies. G.S. has acted as speaker for Merck, Gilead, Abbvie, Novonordisk, Novartis, and Pfizer; served as an advisory board member for Pfizer, Merck, Novartis, Gi-lead, Allergan, and Intercept; and has received unrestricted research funding from Merck and Theratec. T.T.B. has served as a consultant to ViiV Healthcare, Gilead Sciences, Merck, Janssen, and Theratechnologies. M.B. has received travel and research grants from and has been advisor for Janssen, Roche, ViiV, Bristol-Myers Squibb, Merck Sharp & Dohme, Gilead, Mylan, Cipla, Teva, and Novavax. M.G. receives grant support from Gilead. K.M.E. receives grant support from Gilead and has served as a consultant to ViiV Healthcare and Theratechnologies.
Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - The number of people with HIV (PWH) aged 50 years or older continues to steadily increase. The convergence of age-and HIV-related complications in these individuals presents a challenge for both patients and clinicians alike. New findings continue to emerge, as numerous researchers evaluate the combined impact of these two factors on quality of life, physiological systems, and mental health in PWH. Since its first occurrence in 2009, the International Workshop on HIV and Aging has served as a multidisciplinary meeting to share basic biomedical data, clinical trial results, treatment strategies, and epidemiological recommendations, toward better understanding and outcomes among like-minded scientific professionals. In this article, we share a selection of key findings presented in plenary talks at the 11th Annual International Workshop on HIV and Aging, held virtually from September 30, 2020 to October 2, 2020. We will also address the future directions of HIV and aging research, to further assess how the aging process intersects with chronic HIV.
AB - The number of people with HIV (PWH) aged 50 years or older continues to steadily increase. The convergence of age-and HIV-related complications in these individuals presents a challenge for both patients and clinicians alike. New findings continue to emerge, as numerous researchers evaluate the combined impact of these two factors on quality of life, physiological systems, and mental health in PWH. Since its first occurrence in 2009, the International Workshop on HIV and Aging has served as a multidisciplinary meeting to share basic biomedical data, clinical trial results, treatment strategies, and epidemiological recommendations, toward better understanding and outcomes among like-minded scientific professionals. In this article, we share a selection of key findings presented in plenary talks at the 11th Annual International Workshop on HIV and Aging, held virtually from September 30, 2020 to October 2, 2020. We will also address the future directions of HIV and aging research, to further assess how the aging process intersects with chronic HIV.
KW - HIV
KW - aging
KW - antiretroviral therapy
KW - clinical outcomes
KW - neuroscience
UR - http://www.scopus.com/inward/record.url?scp=85118919880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118919880&partnerID=8YFLogxK
U2 - 10.1089/aid.2021.0059
DO - 10.1089/aid.2021.0059
M3 - Article
C2 - 34405689
AN - SCOPUS:85118919880
SN - 0889-2229
VL - 37
SP - 807
EP - 820
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 11
ER -